- Home
- MRK vs NVO Comparison
MRK vs NVO Comparison
Compare MRK & NVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MRK | NVO |
|---|---|---|
| Founded | 2000 | 1923 |
| Country | United States | Denmark |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 268.7B | 269.6B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | MRK | NVO |
|---|---|---|
| Price | $117.15 | $49.04 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 13 | 10 |
| Target Price | ★ $121.00 | $54.25 |
| AVG Volume (30 Days) | 14.0M | ★ 27.8M |
| Earning Date | 02-03-2026 | 02-04-2026 |
| Dividend Yield | ★ 2.89% | 2.49% |
| EPS Growth | ★ 8.01 | 1.77 |
| EPS | ★ 7.28 | 3.62 |
| Revenue | ★ $65,011,000,000.00 | $48,588,245,669.00 |
| Revenue This Year | $5.02 | $1.02 |
| Revenue Next Year | $5.31 | $6.81 |
| P/E Ratio | $16.16 | ★ $13.64 |
| Revenue Growth | 1.31 | ★ 6.43 |
| 52 Week Low | $73.31 | $43.08 |
| 52 Week High | $122.66 | $93.80 |
Technical Indicators
Market Signals| Indicator | MRK | NVO |
|---|---|---|
| Relative Strength Index (RSI) | 63.15 | 39.90 |
| Support Level | $106.03 | $43.24 |
| Resistance Level | $122.46 | $51.09 |
| Average True Range (ATR) | 3.05 | 2.18 |
| MACD | 0.62 | -1.69 |
| Stochastic Oscillator | 67.68 | 27.70 |
Price Performance
Historical ComparisonAbout MRK Merck & Company Inc. (new)
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform, led by Keytruda, is a major contributor to overall sales. The company also has a substantial vaccine business aimed at preventing pediatric diseases, as well as Gardasil for human papillomavirus. Additionally, Merck sells animal health-related drugs. From a geographical perspective, 47% of the company's sales are generated from US human health (pharmaceuticals and vaccines).
About NVO Novo Nordisk A/S
With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.